LEEI Consortium

9

Years of experience

3

Partners

1

Aim


The „LEEI Consortium“ brings together three dynamic partners – KyooBe Tech, Bausch+Ströbel, and Fraunhofer – in a thrilling interdisciplinary collaboration.

 In a groundbreaking and forward-thinking methodology, we employ electron beams for the inactivation of pathogens. This revolutionary approach not only enhances production efficiency, but also elevates vaccine quality, removing hazardous chemicals and ensures process reproducibilitvy.



KyooBe Tech is an emerging engineering company focusing on the development of innovative manufacturing platforms, that drives the pharmaceutical production of tomorrow. With an interdisciplinary team of motivated engineers and biotechnologists, we develop high-quality technological solutions for biological challenges in vaccines and cell and gene therapy. Our vision is to enable access of next-generation therapeutic methods to a broader patient population.


The filling and packaging lines from Bausch+Ströbel are used worldwide to fill syringes, vials, cartridges and ampoules with high-grade liquid and powder pharmaceutical products. Their expertise in the construction of GMP-compliant pharmaceutical systems is unmatched in the industry. Their level of quality & hygienic designs makes them to a vital partner in the LEEI-Consortiums mission.


Four Fraunhofer institutes lead the scientific forefront of this technology, continuously innovating and exploring new applications of LEEI-technologies. They conduct extensive pathogen studies to identify potential vaccine candidates, while also spearheading the development of the prototype system.



Our journey

2012

First virus inactivation

2012
2013

Innovation project granted by the Fraunhofer innovations fund

2013
2014

Filing of LEEI patent family 

2014
2016

Grant by Bill & Melinda Gates Foundation

2016
2019

Licensing deal with Bausch+Ströbel

2019
2020

Foundation of KyooBe Tech GmbH

2020
2022

Launch of KyooBe Techs first LEEI 2.0 prototype  

2022
2024

KyooBe Tech enters the market with it’s first Lab Scale Pilot Device

2024

Parcipitate in a new generation of vacccine manufacturing!

Get in contact to learn and participate!